Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia – unicentric study

Imatinib has been the standard of care in chronic myelogenous leukemia for fifteen years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research